Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial fo... ( MONTREAL July 31 /- Aegera Therap...)

Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156

Date:7/31/2008

MONTREAL, July 31 /PRNewswire/ -- Aegera Therapeutics Inc. is pleased to announce the dosing of the first patient in a fifth phase 1 and 2 clinical oncology study of AEG35156, a second generation antisense therapeutic targeting XIAP, a key member of the Inhibitor of Apoptosis protein family.

The study, made possible, in part, by funding from The Leukemia & Lymphoma Society, is entitled "A Phase 1-2, Multicenter, Open-Label Study of the X- Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Follicular Lymphoma." It is being conducted at the Princess Margaret Hospital (PMH) located in Toronto, Ontario, and is led by Principal Investigator Dr. Christine Chen, with co-Principal Investigators Dr. Aaron Schimmer and Dr. Joe Brandwein, all from the PMH's Department of Hematology and Oncology.

The primary objective of this study is to determine the recommended dose of AEG35156 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL), and to determine the safety profile and response rate to AEG35156 in these patient populations.

"Preliminary evidence of activity in lymphoma was observed in phase 1 studies with AEG35156," stated Dr. Jacques Jolivet, Aegera's VP Clinical. "This clinical trial will specifically study the role played by XIAP knockdown in inducing antitumor activity in CLL, SLL and FL."

"Our clinical program around AEG35156 continues to expand and broaden as we seek to move this therapeutic forward to approval," added Aegera's President and Chief Executive Officer, Dr. Michael J. Berendt. "By adding these lymphoma indications to AEG35156's ongoing phase 1 and 2 studies in leukemia (AML), pancreatic, breast, and non-small cell lung cancer, we continue to seek to position AEG35156 as an important therapeutic option that could address important unme
'/>"/>

SOURCE Aegera Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
2. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
3. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
8. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
9. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
10. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
11. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine

Post Your Comments:

(Date:11/25/2009)...PRNewswire-FirstCall/ -- American Scientific Resou...leased to announce that they have opened a regiona...anghai, China. ,, ASR has been able to secure a...or the development and production of current and f...adults to be distributed and sold globally. Curre...

(Date:11/25/2009)...d, Nov. 25 From November 16-18, P...ing solutions, presented the second edition of the...he special needs of the older population. The conf...nd audiology from around the world and more than 2...with hearing loss for an opportunity to share expe...

(Date:11/25/2009)...25 AMPAC Fine Chemicals LLC (AFC),...daq: APFC ) announced today that it received the ...ard at the Annual Statewide Environmental Summit, ...nology Association (CMTA), the Industrial Environm...Council of California (CICC) held in San Diego. T...

Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2 Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2 Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3 AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2 AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3 China Biopharmaceuticals Holdings Inc Shareholders Overwhelmingly Support Merger with NeoStem Inc a NYSE AMEX Listed Company Trading Under Symbol 5829 1 China Biopharmaceuticals Holdings Inc Shareholders Overwhelmingly Support Merger with NeoStem Inc a NYSE AMEX Listed Company Trading Under Symbol 5829 2 China Biopharmaceuticals Holdings Inc Shareholders Overwhelmingly Support Merger with NeoStem Inc a NYSE AMEX Listed Company Trading Under Symbol 5829 3 Practice changing cancer studies presented at major cancer meeting 60320 1 Practice changing cancer studies presented at major cancer meeting 60320 2 Placental precursor stem cells require testosterone free environment to survive 10574 1 Placental precursor stem cells require testosterone free environment to survive 10574 2

[0] American Scientific Resources Inc. Opens Shanghai Location [0] Phonak Successfully Hosts Hearing Care for Adults 2009 Conference [0] AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit

...Boston Scientific Corporation (NYSE: BSX ) today... program that show real-word survival rates for im...from clinical trials. ALTITUDE analyzes outcomes ...tient Management system. Five-year survival rate ...efibrillators (ICDs) and cardiac resynchronization...

...) (certolizumab pegol), a treatment option for adu...arthritis and moderate to severe Crohn,s disease, ...led syringe resulting from the UCB partnership wit...irectly involved with UCB and OXO(R) in the develo... -- Cimzia(R) prefilled syringe designed to make ...

Other Medicine Technology:Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials 2 Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials 3 Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials 4 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 2 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 3 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 4 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 5 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 6 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 7 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 8 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 9 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 10 Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 11

Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

(Date:11/28/2009)...udy finds gene variation believed to affect circad...althDay News) -- New research suggests that an int... factor in the development of bipolar disorder in ...nation of the genetic makeup of 152 children with ...e to major mood swings, and 140 children without t...

(Date:11/27/2009)... Biotech firm Replikins Ltd...the H1N1 virus genomic data. It shows that the le...3.7 (s.d. 4.5) during the virus,s current outbreak...els this week of 2.0 (s.d. 0.1). The H1N1 infectiv... Boston (PRWEB) November 27, 2009 -...

(Date:11/27/2009)..., , NEUILLY-SUR-SEINE, France, Nov. 27 /PR...rican professional cycling team dedicated to ethic...cycling champions, announced today that it will be...Transitions Optical as a new sponsor of the team. ...turer of adaptive eyewear, offering the most advan...

(Date:11/27/2009)...aring rates to bring unprecedented medical, econom...ov. 27 (HealthDay News) -- The number of people wi...uble over the next 25 years, a new study predicts....44.1 million people with the disease, up from 23.7...f treating people with diabetes will triple, the s...

(Date:11/27/2009)... Specialist manufacturers w...oducts are saving millions of dollars by bringing ...process. Increasing numbers of pro-active medical ...erts at the concept stage of their projects, ensur...ing design processes or potentially outdated techn...

Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3 Health News:Diabetes Cases Expected to Double in 25 Years 2 Health News:Diabetes Cases Expected to Double in 25 Years 3 Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2 Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3 Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4

[0] Bipolar Disorder May Be Tied to Body Clock [0] Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased [0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor [0] Diabetes Cases Expected to Double in 25 Years [0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells

...MINNEAPOLIS, Nov. 5 ATS Medical, Inc.,(Nasdaq: A...rt cardiac,surgery products, announced today that ... Global Investment Conference at the New York Pala...tp://www.newscom.com/cgi-bin/prnh/20040202/ATSILOG...

...A well-informed consumer will be a healthy one, to...- Getting a prescription filled is such a routine ... , And that,s potentially a big mistake, according... to make themselves "medicine smart" by asking que...

...RICHMOND, Va., Nov. 5 Insmed Inc. (Nasdaq:,INSM),...euticals, announced,today that Dr. Geoffrey Allan,...esident of Insmed Therapeutic Proteins, will be pr... participate on a follow-on biologics-focused pane...

...PITTSBURGH, Nov. 5 CardiacAssist, Inc. announced ...ith the TandemHeart System,performing at least one....,In addition, the quarter ending September 30th s...ough nine months of 2008,CardiacAssist has also se...

...2009 GAAP Diluted EPS Guidance Reflects Growth of ... Third-Quarter Highlights:, -- GAAP diluted EPS...39 in third-quarter 2007 -- Diluted EPS, ex... -- Both GAAP diluted EPS, and diluted EPS exclud...

...60,000 Resources Have Been Identified and More Are... 5 The Resource Detectives,program, developed by ...A),provides a virtual volunteer opportunity for an...tectives program,energized a group of 4,000 "detec...

ATS Medical to Participate at the Rodman & Renshaw Annual Global Investment Conference When It Comes to Prescription Drugs, Get Smart Insmed to Present at Upcoming Healthcare Conferences CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results Medco Reports Record Third-Quarter 2008 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63 Multiple Sclerosis Association of America's Resource Detectives(SM) Program Marks One Year Anniversary

...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...

Medicine Products:

Benzodiazepines Detection Benzodiazepines Confirmation/Quantitation, Urine Bendiocarb, Serum or Plasma Bence Jones Protein, Quantitative Kappa, Urine

Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial fo...( MONTREAL July 31 /- Aegera Therap...),Health